Synonyms: ACY-1215
Compound class:
Synthetic organic
Comment: Rocilinostat is an investigational HDAC6 inhibitor [2]. But note that it exhibits only ~10-fold enzymic selectivity against the class I isoform, HDAC1.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Click here to link to ClinicalTrials.gov's full list of ricolinostat studies. |
Mechanism Of Action and Pharmacodynamic Effects |
Rocilinostat inhibits HDAC6 >10 fold more potently than any other HDAC isozyme [2]. Selective inhibition of the class II HDAC isoforms, such as HDAC6, is believed to have the potential to circumvent the reported toxicity associated with inhibition of the class I isoforms [1]. |